Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina (CROSBI ID 271769)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Pejanović-Škobić, Nataša ; Marković, Ivana ; Božina, Nada ; Bašić, Silvio
engleski
Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina
Objective We assessed the influence of the SCN2A gene polymorphism c.56 G > A rs17183814 on the response to lamotrigine monotherapy in patients with focal epilepsy in Herzegovina area, Bosnia and Herzegovina. Material and methods For SCN2A polymorphism c.56 G > A rs17183814, one hundred patients with epilepsy who were receiving lamotrigine in monotherapy and seventy-one age and sex matched healthy controls were genotyped using TaqMan assay. All patients were Caucasians from the region of Herzegovina, Bosnia and Herzegovina. Genotyping was conducted using a polymerase chain reaction in real time. Patients were divided into two groups: responders and non-responders. Results Of all patients with epilepsy, 33% were non- responders, and 67% were responders. The mean age of non-responders was 38.8 vs. group of responders in which it was 35.2. Mean age of onset of seizures in epilepsy patients was 26.7 for non- responders and 25.4 for responders. In patients with epilepsy, the mean age of seizure onset was 26.7 for non-responders and 25.4 for responders. For SCN2A c.56 G > A gene polymorphism, we did not observe any significant differences in genotypic or allelic frequency between patients with epilepsy and healthy controls. Genotype or allelic frequencies of SCN2A c.56 G > A gene polymorphism did not significantly differ for AG or GG genotypes in the non-responders vs. responders. Conclusion There was no significant association in patients with focal epilepsy between studied genotypes and response to lamotrigine monotherapy in Herzegovina patients with focal epilepsy. However, we need studies in a bigger cohort of patients with epilepsy to be assessed in the future.
Epilepsy ; Gene polymorphism ; SCN2A ; Lamotrigine
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
158
2019.
106221
4
objavljeno
0920-1211
1872-6844
10.1016/j.eplepsyres.2019.106221
Povezanost rada
Kliničke medicinske znanosti